Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Genmab A/S has been rated as a "Moderate Buy" by ten brokerages, with six recommending buy and one strong buy rating.
• The average 12-month target price for Genmab A/S shares is $39.25, reflecting analysts' expectations for future stock performance.
• In its latest earnings report, Genmab A/S posted earnings per share of $0.54, exceeding expectations and showing a net margin of 37.53%.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $40.00.

A number of equities analysts have issued reports on the stock. Truist Financial boosted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. HC Wainwright lifted their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price on the stock in a research note on Tuesday. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th.

Genmab A/S Stock Performance

NASDAQ:GMAB traded up $0.24 during trading hours on Friday, reaching $28.84. The company's stock had a trading volume of 718,393 shares, compared to its average volume of 1,437,616. The firm has a market capitalization of $18.50 billion, a price-to-earnings ratio of 14.49, a PEG ratio of 1.65 and a beta of 0.93. The firm has a 50-day simple moving average of $24.38 and a 200-day simple moving average of $21.83. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $28.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of GMAB. Squarepoint Ops LLC boosted its stake in Genmab A/S by 1,235.0% during the fourth quarter. Squarepoint Ops LLC now owns 117,507 shares of the company's stock worth $2,452,000 after acquiring an additional 108,705 shares in the last quarter. Vise Technologies Inc. lifted its stake in shares of Genmab A/S by 41.7% in the fourth quarter. Vise Technologies Inc. now owns 12,892 shares of the company's stock worth $269,000 after buying an additional 3,794 shares in the last quarter. GTS Securities LLC bought a new position in shares of Genmab A/S in the fourth quarter worth approximately $1,552,000. Mackenzie Financial Corp bought a new position in shares of Genmab A/S in the fourth quarter worth approximately $689,000. Finally, Employees Retirement System of Texas bought a new position in shares of Genmab A/S in the fourth quarter worth approximately $1,648,000. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.